Payment overview · 2025
General Payments
$3,950.01
176 reported records · 33 companies
Healthcare provider profile · identity verified
Roger C Roque, MD
Allopathic & Osteopathic Physicians|Family Medicine · EUSTIS, FL · NPI 1437156916
Verified facts
What the public records show
CMS Open Payments records show Roger C Roque, MD received $3,950.01 in general payments during 2025 across 176 reported records.
ABBVIE INC. accounted for 9.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 54 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Entresto, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rexulti, Trintellix, Ubrelvy, Vraylar, Xifaxan, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 336 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 409 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 373 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nexlizet by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 409 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Tresiba by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 373 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $361.17 | 9.1% | 18 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $317.33 | 8.0% | 16 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $287.88 | 7.3% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $285.63 | 7.2% | 12 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$269.91 | 6.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $230.99 | 5.8% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $222.57 | 5.6% | 12 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $199.28 | 5.0% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $163.75 | 4.2% | 10 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $144.14 | 3.6% | 11 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $143.56 | 3.6% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $119.88 | 3.0% | 5 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $119.45 | 3.0% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $107.21 | 2.7% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $94.11 | 2.4% | 3 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $89.43 | 2.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $87.07 | 2.2% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $83.44 | 2.1% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.37 | 1.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $73.64 | 1.9% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $70.32 | 1.8% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $55.20 | 1.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.32 | 1.2% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.22 | 1.2% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $42.21 | 1.1% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $37.65 | 0.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.53 | 0.9% | 2 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $34.98 | 0.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.50 | 0.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.37 | 0.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.15 | 0.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.81 | 0.5% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.94 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,932.63 | 175 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $317.33 | 16 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $312.25 | 11 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $230.99 | 12 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $202.09 | 11 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $199.28 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $193.14 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $186.74 | 8 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $163.75 | 10 | 2025 |
Source payment records
|
|||||
| PROTEGE RX Normalized: protege rx |
Device | Medtronic, Inc. | $152.97 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $144.14 | 11 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $143.56 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $139.37 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $126.59 | 6 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $116.94 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $102.07 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $94.11 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $93.65 | 6 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $89.43 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $87.07 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $86.58 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $85.22 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $83.44 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $82.74 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $70.32 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $63.76 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $63.76 | 4 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $61.09 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $61.09 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $60.29 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.79 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $54.22 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $54.22 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.74 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $49.32 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $47.22 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $46.92 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $42.71 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $42.21 | 2 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $40.65 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $40.00 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $37.65 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $37.53 | 2 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $34.98 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $34.30 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.73 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.66 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 373 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 67 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 336 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 103 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 409 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 183 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 197 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 62 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 63 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
82 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
63 | 13 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
336 | 65 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
409 | 97 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
373 | 97 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
409 | 97 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
183 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
67 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
197 | 43 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
373 | 97 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
42 | 40 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
103 | 15 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 823 | 237 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 660 | 219 |
| Levothyroxine Sodium | Levothyroxine Sodium | 623 | 186 |
| Amlodipine Besylate | Amlodipine Besylate | 599 | 201 |
| Metoprolol Succinate | Metoprolol Succinate | 489 | 175 |
| Potassium Chloride | Potassium Chloride | 423 | 135 |
| Lisinopril | Lisinopril | 410 | 130 |
| Jardiance | Empagliflozin | 409 | 97 |
| Alprazolam | Alprazolam | 388 | 100 |
| Furosemide | Furosemide | 378 | 134 |
| Eliquis | Apixaban | 373 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 361 | 152 |
| Farxiga | Dapagliflozin Propanediol | 336 | 65 |
| Gabapentin | Gabapentin | 328 | 93 |
| Metoprolol Tartrate | Metoprolol Tartrate | 322 | 112 |
| Trazodone Hcl | Trazodone Hcl | 313 | 90 |
| Oxycodone Hcl | Oxycodone Hcl | 296 | 57 |
| Losartan Potassium | Losartan Potassium | 273 | 94 |
| Allopurinol | Allopurinol | 271 | 91 |
| Tamsulosin Hcl | Tamsulosin Hcl | 270 | 88 |
| Metformin Hcl | Metformin Hcl | 241 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 236 | 49 |
| Carvedilol | Carvedilol | 230 | 69 |
| Clopidogrel | Clopidogrel Bisulfate | 220 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 210 | 65 |
| Pregabalin | Pregabalin | 207 | 42 |
| Ozempic | Semaglutide | 197 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 194 | 42 |
| Montelukast Sodium | Montelukast Sodium | 193 | 64 |
| Omeprazole | Omeprazole | 186 | 66 |
| Mounjaro | Tirzepatide | 183 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 179 | 57 |
| Ropinirole Hcl | Ropinirole Hcl | 179 | 50 |
| Sertraline Hcl | Sertraline Hcl | 171 | 42 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 168 | 136 |
| Clonazepam | Clonazepam | 167 | 40 |
| Spironolactone | Spironolactone | 167 | 62 |
| Dexamethasone | Dexamethasone | 166 | 127 |
| Tizanidine Hcl | Tizanidine Hcl | 166 | 51 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 164 | 37 |
| Simvastatin | Simvastatin | 151 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 143 | 52 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 135 | 134 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 133 | 49 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 126 | 18 |
| Mirtazapine | Mirtazapine | 126 | 49 |
| Baclofen | Baclofen | 123 | 35 |
| Xarelto | Rivaroxaban | 106 | 23 |
| Metolazone | Metolazone | 105 | 30 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 105 | 85 |
| Famotidine | Famotidine | 104 | 30 |
| Gemtesa | Vibegron | 103 | 15 |
| Divalproex Sodium | Divalproex Sodium | 99 | 24 |
| Lorazepam | Lorazepam | 99 | 28 |
| Donepezil Hcl | Donepezil Hcl | 98 | 28 |
| Enalapril Maleate | Enalapril Maleate | 95 | 32 |
| Prednisone | Prednisone | 95 | 46 |
| Meloxicam | Meloxicam | 93 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 91 | 25 |
| Repatha Sureclick | Evolocumab | 91 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 28 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 87 | 30 |
| Glipizide Er | Glipizide | 87 | 26 |
| Glyxambi | Empagliflozin/Linagliptin | 87 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 85 | 79 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 82 | 25 |
| Synthroid | Levothyroxine Sodium | 82 | 27 |
| Tramadol Hcl | Tramadol Hcl | 80 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 78 | 52 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 73 | 58 |
| Morphine Sulfate Er | Morphine Sulfate | 73 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 17 |
| Estradiol | Estradiol | 72 | 25 |
| Tresiba Flextouch U-200 | Insulin Degludec | 69 | 22 |
| Cefdinir | Cefdinir | 68 | 67 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 18 |
| Finasteride | Finasteride | 68 | 18 |
| Levetiracetam | Levetiracetam | 68 | 17 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 68 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 19 |
| Entresto | Sacubitril/Valsartan | 67 | 16 |
| Clonidine Hcl | Clonidine Hcl | 66 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 17 |
| Folic Acid | Folic Acid | 63 | 20 |
| Vraylar | Cariprazine Hcl | 63 | 13 |
| Rexulti | Brexpiprazole | 62 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 62 | 23 |
| Azithromycin | Azithromycin | 60 | 55 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 16 |
| Cefuroxime | Cefuroxime Axetil | 57 | 51 |
| Ezetimibe | Ezetimibe | 57 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 28 |
| Fluconazole | Fluconazole | 55 | 34 |
| Levofloxacin | Levofloxacin | 55 | 48 |
| Bumetanide | Bumetanide | 54 | 21 |
| Midodrine Hcl | Midodrine Hcl | 53 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 23 |
| Lactulose | Lactulose | 52 | 22 |
| Latanoprost | Latanoprost | 51 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 26 |
| Glimepiride | Glimepiride | 48 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 18 |
| Sucralfate | Sucralfate | 47 | 25 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 46 | 18 |
| Propranolol Hcl | Propranolol Hcl | 46 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 35 |
| Aripiprazole | Aripiprazole | 44 | 11 |
| Bupropion Xl | Bupropion Hcl | 44 | 17 |
| Glipizide | Glipizide | 44 | 14 |
| Kerendia | Finerenone | 44 | suppressed |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Cephalexin | Cephalexin | 42 | 37 |
| Hydromorphone Hcl | Hydromorphone Hcl | 42 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 42 | 40 |
| Terbinafine Hcl | Terbinafine Hcl | 42 | 22 |
| Atenolol | Atenolol | 41 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | 11 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 41 | 14 |
| Linzess | Linaclotide | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 17 |
| Colchicine | Colchicine | 40 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 11 |
| Digoxin | Digoxin | 39 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 13 |
| Steglatro | Ertugliflozin Pidolate | 37 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 36 | 20 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 36 | 35 |
| Fenofibrate | Fenofibrate | 36 | 11 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | 11 |
| Methocarbamol | Methocarbamol | 35 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 35 | suppressed |
| Ranolazine Er | Ranolazine | 34 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Telmisartan | Telmisartan | 33 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 32 | 14 |
| Indapamide | Indapamide | 32 | 14 |
| Nabumetone | Nabumetone | 32 | suppressed |
| Ssd | Silver Sulfadiazine | 32 | 26 |
| Zenpep | Lipase/Protease/Amylase | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | 12 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 31 | 12 |
| Novolog Flexpen | Insulin Aspart | 31 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 31 | 14 |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | 12 |
| Nifedipine Er | Nifedipine | 30 | 12 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Torsemide | Torsemide | 28 | 12 |
| Clotrimazole | Clotrimazole | 27 | 22 |
| Etodolac | Etodolac | 27 | 16 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 24 |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Calcium Acetate | Calcium Acetate | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 19 |
| Praluent Pen | Alirocumab | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Timolol Maleate | Timolol Maleate | 25 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 24 | suppressed |
| Clonidine | Clonidine | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Ryaltris | Olopatadine Hcl/Mometasone | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Novolog | Insulin Aspart | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Modafinil | Modafinil | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 19 |
| Ammonium Lactate | Ammonium Lactate | 20 | 16 |
| Calcitriol | Calcitriol | 20 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 19 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | 13 |
| Tresiba | Insulin Degludec | 19 | suppressed |
| Valsartan | Valsartan | 19 | 11 |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | 16 |
| Fentanyl | Fentanyl | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Nyamyc | Nystatin | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 17 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 17 | suppressed |
| Ubrelvy | Ubrogepant | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 16 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Tadalafil | Tadalafil | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | 11 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Xyosted | Testosterone Enanthate | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 11 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,950.01 · 176 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, AMYVID, Arikayce, Auvelity, BREZTRI, Brinsupri, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, FANAPT, FARXIGA, GEMTESA, GIMOTI, JARDIANCE, KISUNLA, KRYSTEXXA, Kerendia, LEQVIO, LINZESS, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, OFEV, OTEZLA, Ozempic, PREVNAR 20, PROTEGE RX, QULIPTA, REPATHA, REXULTI, Rybelsus, SYMPLICITY G3, Sunosi, TRINTELLIX, TRUDHESA, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, XIFAXAN, YUPELRI, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 27 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error